NASDAQ: LENZLenz Therapeutics Inc Stock
$15.86-0.06 (-0.38%)
Updated Apr 24, 2024
LENZ Price
$15.86
Fair Value Price
$22.77
Market Cap
$131.95M
52 Week Low
$14.07
52 Week High
$29.82
P/E
-1.03x
P/B
0.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$124.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$90M
Beta
1.15
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LENZ Overview
Graphite Bio, Inc. is a clinical-stage company developing therapies to cure a range of serious and life-threatening diseases. Its gene-editing platform enables the correction of mutations, the replacement of entire disease-causing genes with normal genes, or the insertion of new genes into predetermined, safe locations. Known as Integral Medicines, Inc. until 2020, Graphite Bio was incorporated in 2017 and is headquartered in South San Francisco, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LENZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LENZ ($15.86) is undervalued by 30.36% relative to our estimate of its Fair Value price of $22.77 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LENZ ($15.86) is significantly undervalued by 30.36% relative to our estimate of its Fair Value price of $22.77 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LENZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LENZ due diligence checks available for Premium users.
Be the first to know about important LENZ news, forecast changes, insider trades & much more!
LENZ News
Valuation
LENZ fair value
Fair Value of LENZ stock based on Discounted Cash Flow (DCF)
Price
$15.86
Fair Value
$22.77
Undervalued by
30.36%
LENZ ($15.86) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LENZ ($15.86) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LENZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LENZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.03x
Industry
15.69x
Market
41.27x
LENZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.72x
Industry
5.86x
LENZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LENZ's financial health
Profit margin
Revenue
$0.0
Net Income
-$22.9M
Profit Margin
0%
LENZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$188.5M
Liabilities
$4.9M
Debt to equity
0.03
LENZ's short-term assets ($188.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LENZ's short-term assets ($188.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LENZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$45.9M
Investing
$47.1M
Financing
$66.0k
LENZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LENZ vs Biotech Stocks
Lenz Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.